DOCSLIB.ORG

Covid 19 Essay in Hindi Wikipedia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Covid 19 Essay in Hindi Wikipedia 1 Covid 19 Essay In Hindi Wikipedia Andhra Pradesh had received 370,000 doses of Covishield and 20,000 of Covaxin. The second dose was provided from 15 February onwards. According to India s Union Ministry of Health and Family Welfare, the most common side-effects include pain or swelling at the injection site, fever, irritability and headaches. 30 The company aims to produce 100 million doses per month, but by May 2021 its production capacity was only 60 70 million doses. Return to centralised procurement Edit. 139 Vaccination of people in the 18-44 age group with certain medical conditions began in early May, and that of all people in the 40-44 age group began on June 4. Phase 3 On 1 April 2021, all people above the age of 45 are now eligible in this phase. This includes Health Minister KK Shailaja, 133 Chief Minister Pinarayi Vijayan, 134 state police chief Lokanath Behera, 135 former Chief Minister VS Achuthanandan 136 and Thiruvananthapuram District Collector Navajoth Khosa. 5 lakh Covishield doses on its own for the phase 3 immunization. 60 lakh health workers in Punjab will receive a COVID-19 vaccine in the first phase, after that frontline worker and then people over the age of 50 or with co-morbid conditions. 84 On 20 April 2021, Bharat Biotech announced that it had expanded its production capabilities for Covaxin to 700 million doses per-year. 0 Crores which will be open for bidding from 8 June to 22 June 2021. 54 On 3 June, the Ministry of Health and Family Welfare pre-ordered 300 million doses of a potential fourth vaccine, Corbevax, which is undergoing phase 3 clinical trials. The pace of immunization has picked up and there are more than 2. The state aims to vaccinate 32,000 people a day. In September 2020, India s Health minister Harsh Vardhan stated that the country planned to approve and begin distribution of a vaccine by the first quarter of 2021. Phase 1b Vaccination of the frontline worker including police, local bodies, disaster management, rural development and panchayats and revenue departments will be starting from 1 February 2021. These changes were intended to help expedite the availability of vaccines already in use in other countries. 177 Medical experts maintain that vaccines used are safe and their benefits outweigh the risks. However, on the first two days, only 61 and 47. COVID-19 vaccination in India. 293,706,832 people with at least one dose administered of Covaxin or Oxford AstraZeneca vaccine or Sputnik V 67,616,716 people have been fully vaccinated with both doses of Covaxin or Oxford AstraZeneca vaccine or Sputnik V 21 of the Indian population has received at least one dose. 52 53 On 25 May, India exceeded 200 million vaccine doses administered in total. However, the documentation had been completed only in 3500 cases. One person was admitted to hospital following complications regarding vaccine, but was later discharged. 78 79 The government ordered 21 million doses to be delivered by February, but the company said no indication of any further orders were given. 06 crores 26,69,33,878 5,67,29,419 32,36,63,297 27 5 Andaman and Nicobar Islands 3,80,581 1,45,019 16,306 1,61,325 38 4 Andhra Pradesh 4,95,77,103 1,19,58,636 29,10,171 1,48,68,807 24 6 Arunachal Pradesh 13,83,727 4,75,959 81,866 5,57,825 34 6 Assam 3,12,05,576 56,68,538 11,86,267 68,54,805 18 4 Bihar 10,40,99,452 1,09,79,659 19,86,711 1,29,66,370 11 2 Chandigarh 10,55,450 4,21,745 82,381 5,04,126 40 8 Chhattisgarh 2,55,45,198 74,57,184 14,68,963 89,26,147 29 6 Dadra and Nagar Haveli 3,43,709 1,63,092 15,656 1,37,685 47 5 Daman and Diu 2,43,247 1,83,618 17,309 2,00,927 75 7 Delhi 16,787,941 56,36,415 17,02,823 73,39,238 34 10 Goa 14,58,545 7,62,730 1,08,743 8,71,473 52 7 Gujarat 6,04,39,692 1,95,00,497 53,87,325 2,48,87,822 32 9 Haryana 2,53,51,462 71,66,208 13,07,304 84,73,512 28 5 Himachal Pradesh 68,64,602 30,25,895 4,71,889 34,97,784 44 7 Jammu and Kashmir 1,22,67,032 37,00,498 6,45,594 43,46,092 30 5 Jharkhand 3,29,88,134 56,40,980 10,28,742 66,69,722 17 3 Karnataka 6,10,95,297 1,81,96,699 35,54,331 1,78,47,653 30 6 Kerala 3,34,06,061 1,05,41,451 29,94,428 1,35,35,879 32 9 Ladakh 2,74,000 1,68,691 47,925 2,16,616 62 17 Lakshadweep 64,473 46,340 7,516 53,856 72 12 Madhya Pradesh 7,26,26,809 1,74,66,939 23,59,925 1,98,26,864 24 3 Maharashtra 11,23,74,333 2,51,45,226 60,14,297 3,11,59,523 22 5 Manipur 25,70,390 5,33,686 73,067 6,06,753 21 3 Meghalaya 29,66,889 5,87,788 76,522 6,64,310 20 3 Mizoram 10,97,206 4,97,356 53,240 4,10,438 45 5 Nagaland 19,78,502 4,07,669 54,869 4,62,538 21 3 Odisha 4,19,74,219 95,41,255 20,30,467 1,15,71,722 23 5 Puducherry 12,47,953 4,18,646 63,226 4,81,872 34 5 Punjab 2,77,43,338 60,30,088 9,78,243 70,08,331 22 4 Rajasthan 6,85,48,437 2,04,13,290 38,38,633 2,42,51,923 30 6 Sikkim 6,10,577 3,71,539 61,597 4,33,136 61 10 Tamil Nadu 7,21,47,030 1,25,36,293 24,86,780 1,50,23,073 17 3 Telangana 3,50,03,674 89,45,614 14,85,529 1,04,31,143 26 4 Tripura 36,73,917 18,99,649 5,74,902 24,74,551 52 16 Uttar Pradesh 19,98,12,341 2,61,54,182 43,25,246 3,04,79,428 13 2 Uttarakhand 1,00,86,292 34,43,234 7,71,457 42,14,691 34 8 West Bengal 9,12,76,115 1,63,82,716 47,46,182 2,11,28,898 18 5 Miscellaneous 17,35,385 15,17,666 32,53,051 As of June 28, 2021 7 00 AM IST 120. 174 The state government had procured one lakh Covaxin doses and 3. 81 In June 2020, it received DCGI approval to begin phase 1 and phase 2 trials on its vaccine, BBV152 trade name Covaxin. Sudhakar announced on 9 January that the state would be given 13. 131 After vaccinating 3. The remainder would be offered to individual states and pur- chased on the open market including private hospitals , which would be able to serve residents over the age of 18. Madhya Pradesh Edit. India initially approved the Oxford AstraZeneca vaccine manufactured under license by Serum Institute of India under the trade name Covishield and Covaxin a vaccine developed locally by Bharat Biotech. 17 billion more vaccine doses from August to December 2021. Bihar received 569,000 doses of the vaccine. Uttar Pradesh was the first state to vaccinate over 20 lakh people. 8 The first recipients were to be 30 million health workers directly dealing with COVID patients. Reddy s Laboratories stated that it planned to have the vaccine available in India by late-May 2021. They have since been joined by the Sputnik V manufactured under license by Dr. 17 Each vaccination centre will offer either Covishield or Covaxin, but not both. 14,883 health workers in Maharashtra given COVID-19 vaccine on Tuesday 147 In Mumbai, only 1,926 people could be vaccinated on the first day, due to a combination of low turnout and technical problems with the software. Please note that this data is interim, so, the information is subject to change as per new official updates from health officials. 92 93 In April 2021, RDIF CEO Kirill Dmitriev told NDTV that they had five great manufacturers in India who would be producing the vaccine, and felt that the country could become Sputnik V s production hub for use and export. 142 Other States such as Karnataka have launched similar efforts which have garnered little success. Maharashtra Edit. 162 In a review meeting held in January 2021 by the state government, the state head of World Health Organization said that Rajasthan is the best state in terms of preparation for COVID vaccination. 45 46 47 An estimated 156 million doses is expected between August and December; initially, doses will be sourced from Russia, but domestic production is expected to begin by August 2021. There were two cases of adverse events, but neither required hospitalization. 76 The SII planned to manufacture 1. Hyderabad-based Bharat Biotech, in collaboration with U. Graph of daily doses administered across the country Edit. Uttar Pradesh Edit. The vaccination drive was temporarily suspended due to the technical glitches in the software alerting people to their vaccination appointments.
Load more

Recommended publications
  • What Do We Know About India's Covaxin Vaccine?
    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
    [Show full text]
  • India - the Netherlands Virtual Summit Friday, April 9, 2021
    India - The Netherlands Virtual Summit Friday, April 9, 2021 Joint Statement on India-The Netherlands Virtual Summit - Towards a Strategic Partnership on Water Shri Narendra Modi, Prime Minister of the Republic of India, and H.E. Mr. Mark Rutte, Prime Minister of the Netherlands, co-chaired a Virtual Summit between India and the Netherlands on April 9, 2021. 2. The two Prime Ministers recalled their previous meetings in 2015, 2017 and 2018 as well as the successful visit of the King and the Queen of the Netherlands to India in 2019 and welcomed the steadfast development of bilateral relations that are underpinned by the shared values of democracy, rule of law, pluralism, equality, freedom of speech and respect for human rights and the historic bonds of friendship between the two countries. They held an in- depth exchange of views on further deepening the bilateral relationship in wide-ranging areas of cooperation including trade and economy, water management and agriculture sector, smart cities and urban mobility, science & technology cooperation, public health & health care and space. 3. In the context of new geopolitical and geoeconomic realities, they also shared views on regional and global issues of mutual interest including post-Covid economic recovery, climate change and the Indo-Pacific. They reiterated their strong commitment to a rules- based multilateral order for ensuring international peace, stability and prosperity. Fight against COVID-19 Pandemic 4. The two leaders commended the selfless contribution of healthcare workers and other frontline staff across the globe in the fight against the pandemic. Both leaders reiterated their commitment to ensure equitable and affordable access to Covid19 vaccines to all countries and agreed to cooperate in this regard.
    [Show full text]
  • Download File (Pdf)
    2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION 2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION Foreword by Mo Ibrahim Notwithstanding these measures, on current projections Founder and Chair of the Mo Ibrahim Africa might not be adequately covered before 2023. Foundation (MIF) Vaccinating Africa is an urgent matter of global security and all the generous commitments made by Africa’s partners must now be delivered. Looking ahead - and inevitably there will be future pandemics - Africa needs to significantly enhance its Over a year ago, the emergence and the spread of COVID-19 homegrown vaccine manufacturing capacity. shook the world and changed life as we knew it. Planes were Africa’s progress towards its development agendas was off grounded, borders were closed, cities were shut down and course even before COVID-19 hit and recent events have people were told to stay at home. Other regions were hit created new setbacks for human development. With very earlier and harder, but Africa has not been spared from the limited access to remote learning, Africa’s youth missed out pandemic and its impact. on seven months of schooling. Women and girls especially The 2021 Ibrahim Forum Report provides a comprehensive are facing increased vulnerabilities, including rising gender- analysis of this impact from the perspectives of health, based violence. society, politics, and economics. Informed by the latest data, The strong economic and social impacts of the pandemic it sets out the challenges exposed by the pandemic and the are likely to create new triggers for instability and insecurity.
    [Show full text]
  • Bcpct]Ttsbc^Prc U^A Dq[XRV^^S
    6 < %()(=#%% 53%7==,>3='$()6(=#%% (#-'>3='$()6(=#%% $'()"*$+&,- %( !"# $$%& 2(*3-% (566)(37)% 3 0 4 $5 3 $1 2 0 .8 9 8 ++0 0 .:; . !" . / 01 $ %'( $) '# *' it for the last eight to nine notable achievements to its months, “where is the UN in name in the 75 years of its aking a strong case for a this joint fight. Where is the experience, including the pre- Msignificant role for India effective response.” vention of a third world war, in the United Nations, Prime Focussing on a more “we can’t deny terrorist attacks 0 Minister Narendra Modi on prominent role for India in the shook the world”. Saturday stressed the need for UN and fight against corona, “We have successfully ne of the oldest partners changes in the international the Prime Minister avoided avoided a third world war but Oof the BJP — the body and questioned its posi- making any reference to ongo- we cannot deny many wars Shiromani Akali Dal — which tion in fighting the coron- ing tension at the Line of happened, many civil wars has been with it through thick avirus pandemic. Actual Control (LAC) and happened. Terrorist attack and thin for decades, finally He also assured the global frosty ties with Pakistan in his shook the world. Blood was quit the National Democratic Q community that India will pro- 20-minute speech. He also did spilled. Those were killed were Alliance (NDA) on Saturday, vide corona vaccine to the not respond to Pakistan Prime like you and me. Children left signaling a complete political world as it is the world’s biggest Minister Imran Khan’s remarks the world prematurely,” he said.
    [Show full text]
  • In 2020, India Dealt with the First Wave of COVID-19 Pandemic With
    PREFACE n 2020, India dealt with the first wave of COVID-19 pandemic with collective measures, Iscientific approach, and awareness. Undoubtedly the second wave of the pandemic is testing our patience and the extent to which we can all tolerate its fangs. The impact of the second wave has seen shortage of medical oxygen across the nation. But, the intelligent use of technology and well-planned resource allocation to tackle the new wave of the pandemic has been dealt with at a war-footing. The current edition, COVID 2021: Nation’s S&T Efforts Against COVID-19, has been compiled to inform our readers and strengthen the usefulness of any published information. This edition contains compilation and coverage of information related to the capacity enhancement of medical oxygen, start-up spotlights, research contributions, and so on. To bridge the gap among scientific contributions, leadership and administrative efforts, and the perspective of the general public, Vigyan Prasar is continuously reaching out to its audiences in the shape of a regular e-newsletter, taking its mandate of science communication, popularisation and extension to the next level. Our effort is firmly based on the fact that “Science gathers knowledge faster than society gathers wisdom”. The steady increase in the number of recoveries and the significant and continuous decrease in positivity rate provide us the much-needed assurance that this may be the outcome of improving the health infrastructure and making health the cornerstone at the policy level. We wish an engaging reading to our audiences across all strata of the society and look forward to suggestions and feedback at [email protected].
    [Show full text]
  • COVID-19 Vaccines Update Supplement Week Of: 5Th April, 2021
    CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 5th April, 2021 I. Overview of Development and Regulatory Approvals: • 85 candidate vaccines are in clinical development: 16 in Phase 3 trials, and 4 in Phase 4 trials – see Figure in CARPHA COVID-19 Vaccine Regulatory Tracker (Phases tab). • 13 vaccines have received regulatory approvals in various countries, and 16 vaccines are at various stages of engagement with WHO for emergency use listing (EUL). • 4 vaccines have been approved by WHO for Emergency Use Listing: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), and Janssen-Cilag. • 4 additional vaccines are expected to be approved by WHO in April – Tables 1 and 3. • There are 3 additional vaccines being considered by WHO but these are at the stage of submitting expressions of interest: Bharat Biotech, Clover Biopharmaceuticals-GSK + Dynavax, and BioCubaFarma (Cuba). • The WHO Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations and background documents are available for vaccines by: Moderna, Pfizer-BioNTech, AstraZeneca-Oxford and Janssen-Cilag at SAGE Interim Guidance. The recommendations provide guidance on the use the vaccines, including use in various groups. • Reports of rare clotting events among vaccinees continue to be assessed by various regulators. The EU's European Medicines Agency (EMA) has stated that there was no evidence to support decisions by regulators to restrict the use of Oxford-AstraZeneca vaccines in some age groups. The WHO maintains that the benefit-risk balance of the vaccine remains favorable. • CARPHA has shared its COVID-19 vaccine regulatory tracker with Member States for viewing as updates are made.
    [Show full text]
  • Event Summary Report
    1 EVENT SUMMARY REPORT INDIA-NIGERIA: FACING THE COVID-19 PANDEMIC TOGETHER Date: March 30, 2021 Time: 1030-1315 (WAT) Venue: Cisco Webex Virtual Platform Recording Link: https://www.youtube.com/watch?v=L8FpbwhgUdA 1. INTRODUCTION 1.1 The webinar was the first event to be co-hosted by the Gusau Institute (GI) in Nigeria and the Manohar Parrikar Institute for Defence Studies and Analyses (MP-IDSA) in India, and it concentrated on ways to join forces in the fight against COVID-19. Other areas of potential and/ or expanded collaboration were also highlighted during the deliberations. 1.2 The event was divided into two sessions that focused on identifying areas of cooperation between Nigeria and India in controlling the COVID-19 pandemic, and emerging India-Africa cooperation, respectively. The discussions were preceded by an inaugural session co-chaired by the founder of the GI, and the Director General of MP-IDSA, who also led the rest of the programme. (Note: Short profiles of all the participants are attached as Annexure A.) 2. PROGRAMME HIGHLIGHTS 2.1 INAUGURAL SESSION 2.1.1 Opening Remarks by Amb. Sujan R. Chinoy Director General, MP-IDSA https://www.youtube.com/watch?v=L8FpbwhgUdA (0:45-12:34) 2.1.1.1 Copy of the DG’s remarks follows: Lt. Gen. Aliyu Gusau Mohammed, Founder, Gusau Institute, Amb Abhay Thakur, High Commissioner of India to Nigeria, Mr. Boss Mustapha, Secretary to the Government of the Federation (SGF) & Chairman, Presidential Task Force on COVID-19, Experts from Gusau Institute, Distinguished participants, Good afternoon, 2 Today, we have gathered for the first bilateral event, albeit in virtual mode, between the Manohar Parrikar Institute for Defence Studies and Analyses and the Gusau Institute of Nigeria.
    [Show full text]
  • V.3 1/25/2021 COVID-19 Vaccine FAQ Sheet
    COVID-19 Vaccine FAQ Sheet (updated 1/25/2021) The AST has received queries from transplant professionals and the community regarding the COVID-19 vaccine. The following FAQ was developed to relay information on the current state of knowledge. This document is subject to change and will be updated frequently as new information or data becomes available. What kinds of vaccines are available or under development to prevent COVID-19? There are currently several vaccine candidates in use or under development. In the United States, the Government is supporting six separate vaccine candidates. Several other vaccines are also undergoing development outside of the United States government sponsorship and further information can be found here: • NYTimes Coronavirus Vaccine Tracker: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine- tracker.html • Washington Post Vaccine Tracker: https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update- coronavirus/ The types of vaccines are as follows (January 25, 2021) 1: Table 1: Vaccines Under Development Vaccine Type Compound Name Clinical Trial Notes [Sponsor] Phase mRNA mRNA-1273 Phase 3 Emergency use in [Moderna] U.S., E.U., other countries Approved in Canada BNT162b2 [Pfizer] Phase 2/3 Emergency use in U.S., E.U., other countries Also approved in Canada and other countries Replication- AZD1222 Phase 2/3 Emergency use in defective [AstraZeneca] Britain, India, other adenoviral vector countries (not U.S.) Ad26.COV2.S Phase 3 [Janssen] v.3 1/25/2021 Recombinant- NVX-CoV2373 Phase 3 subunit-adjuvanted [Novavax] protein Recombinant SARS- Phase 1/2 CoV-2 Protein Antigen + AS03 Adjuvant [Sanofi Pasteur/GSK] Inactivated CoVaxin [Bharat Phase 3 Emergency Use in coronavirus Biotech] India BBIBP-CorV Phase 3 Approved China, [Sinopharm] Bahrain, UAE; Emergency use elsewhere (not U.S.) Both of the mRNA SARS-CoV-2 vaccines (Moderna, Pfizer) have been approved by Emergency Use Authorization by the U.S.
    [Show full text]
  • Overview of Aarogya Setu Application Shweta Devidas Kedare1
    International Research Journal of Engineering and Technology (IRJET) e-ISSN: 2395-0056 Volume: 07 Issue: 06 | June 2020 www.irjet.net p-ISSN: 2395-0072 Overview of Aarogya Setu Application Shweta Devidas Kedare1 1Shweta Devidas Kedare, Department of Master of Computer Application, ASM IMCOST, Maharashtra, India ---------------------------------------------------------------------***--------------------------------------------------------------------- Abstract - The app - Aarogya Setu, which means "bridge to health" in Sanskrit -It is an Indian app which was launched on April 2nd 2020, by Indian government. It is designed as a Coronavirus, or COVID-19 contact tracing app that uses the Bluetooth and location technology in phones to note when you are near another user who also uses the Aarogya Setu app. In case someone you have come in close proximity to is confirmed infected, you are alerted. The app alerts are produced by instructions on how to self-isolate and what to do in case you develop symptoms. Basically this app gives basic information about Covid-19, including hygiene and social distancing protocols. It also has details of how one could donate to the prime minister’s coronavirus-specific relief fund, PM-Cares. India has made it mandatory for government and private sector employees to download it But users and experts in India and around the world say the app raises huge data security concerns. KeyWords: security, data, private, information, COVID-19, technology, location, bluetooth, proximity, etc. 1. INTRODUCTION Since the risk of COVID-19 started increasing in India so, The government of India decided to launch the application, name Aarogya Setu, which was intended to monitor the ratio of COVID-19 patients in India .This app is an updated version of an earlier app called Corona Kavach (now discontinued) which was released earlier by the Government of India.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • A Review of India's Contact-Tracing App, Aarogya Setu
    Doc Title A Review of India’s Contact-Tracing App, Aarogya Setu A - Front Page two line title ARTICLE A Review of India’s Contact-tracing App, Aarogya Setu The Government of India’s Ministry of Electronics and Information Technology (MeitY) agency launched Aarogya Setu, a contact-tracing mobile application. Aarogya Setu has been created by the National Informatic Centre (NIC) in response to the COVID-19 crisis, as a way to collect and understand public health-related data.1 The application uses mobile phones to perform a cross reference of individuals’ data with the database held by Indian Council of Medical Research (ICMR), “On various online discussion which was specially created as part of ongoing COVID-19 testing infrastructure. forums, there is significant The purpose of Aarogya Setu is to notify users whether they have been exposed interest in the workings of this to COVID-19, by checking their proximity to known patients. In the event of a government- managed app match, the application will warn other users in the area that an infected person and its use of personal and is in their proximity. According to the press release dated May 26, 2020 available sensitive user data..”123 on mygov.in website, roughly 114 million users have adopted the app.2 Aarogya Setu also collects some sensitive personal information including gender and recent travel information. This has raised privacy and security questions. This whitepaper evaluates the functionality and data privacy aspects of the application. About Aarogya Setu Aarogya Setu app is a self-assessment disease monitoring app launched by the Indian government.
    [Show full text]
  • Covid-19 Tracing Contacts Apps: Technical and Privacy Issues
    Int. J. Advance Soft Compu. Appl, Vol. 12, No. 3, November 2020 ISSN 2074-8523; Copyright © ICSRS Publication, 2020 www.i-csrs.org Covid-19 Tracing Contacts Apps: Technical and Privacy Issues Salaheddin J. Juneidi Computer Engineering Department, Palestine Technical University Khadoorei1, Hebron, West Bank Palestine. e-mail: [email protected] Received 20 July 2020; Accepted 5 October 2020 Abstract Since the start of the year 2020 the world is facing an outbreak of Covid-19 pandemic, technical specialists all over the universe have been scrambling to develop services, apps, and system’s protocols for contactors tracing, with the objective to identify and to notify everyone that gets close with an individual carrier. Some of these apps are lightweight and temporary, while others are diffuse and aggressive. Some of tracing services are developed locally by small interested programmers, while others are large-scale international operations. To date, we have recognized more than 25 large automated contact tracing efforts around the globe, included with details about what they were, how they worked, and the procedures and conditions that were put in place around them. This paper will deal with general data of the most prominent applications in terms of technical approaches used in the world and compare them with regard to the efficiency of tracking covid-19 and compare them with concerning of the people’s privacy who use these apps. Keywords: Covid-19, GPS location, Blue trace, Google/Apple, DP-3T, Apps, Privacy. 1. Introduction Many applications, services and systems have been proposed and launched [1] with an aim to track and identify infected people with objective to reduce or even to prevent physical contact with other people, some of these tracking 1 Special thanks to Palestine Technical University -Khadoorei for continuous support of research efforts Salaheddin J.
    [Show full text]